Table 2.
Basic comparative characteristics depending on the presence of significant Cheyne-Stokes respiration (CSR).
| Variable | Mean ±SD or n (%) | p | |
|---|---|---|---|
| Significant CSR (n=51) | Without significant CSR (n=110) | ||
| Age (years) | 65±10 | 63±11 | 0.251 |
|
| |||
| Male gender | 50 (98) | 100 (90.9) | 0.183 |
|
| |||
| Height [cm] | 174.8±6.7 | 172.7±7.0 | 0.073 |
|
| |||
| Weight [kg] | 88.4±20.2 | 88.7±19.7 | 0.450 |
|
| |||
| BMI [kg/m2] | 29.0±6.5 | 29.6±5.6 | 0.962 |
|
| |||
| HF ischemic etiology | 33 (64.7) | 73 (66.4) | 0.837 |
|
| |||
| Hypertension | 43 (84.3) | 97 (88.2) | 0.497 |
|
| |||
| Permanent atrial fibrillation | 23 (45.1) | 29 (26.4) | 0.018 |
|
| |||
| Stimulation in ECG | 9 (17.6) | 18 (16.4) | 0.839 |
|
| |||
| ICD | 30 (58.8) | 45 (40.9) | 0.034 |
|
| |||
| CRT | 7 (13.7) | 15 (13.6) | 0.988 |
|
| |||
| Cardiac stimulator different from ICD/CRT | 6 (11.8) | 10 (9.1) | 0.597 |
|
| |||
| Blood pressure: | |||
| SBP [mm Hg] | 119.5±15.5 | 126.5±17.9 | 0.031 |
| DBP [mm Hg] | 75.0±11.7 | 74.4±12.2 | 0.674 |
|
| |||
| Medical history (outside cardiology): | |||
| Stroke/TIA | 4 (7.8) | 6 (5.5) | 0.816 |
| Diabetes | 17 (33.3) | 38 (34.6) | 0.880 |
| CODP | 3 (5.9) | 20 (18.2) | 0.067 |
| GFR <60 ml/min/1.73 m2 | 17 (34.7) | 24 (22) | 0.093 |
|
| |||
| Pharmacotheraphy: | |||
| B-blockers | 50 (98) | 107 (97.3) | 0.780 |
| ACE-I | 46 (90.2) | 102 (92.7) | 0.812 |
| ARB | 5 (9.8) | 7 (6.4) | 0.652 |
| Aldosterone antagonists | 41 (80.4) | 87 (79.1) | 0.849 |
| Duretics | 50 (98) | 94 (85.5) | 0.032 |
| Digoxin | 3 (5.9) | 4 (3.6) | 0.815 |
| Amiodarone | 9 (17.7) | 18 (16.4) | 0.839 |
Data presented as means ±SD or as a number (percentage). BMI – body mass index; HF – heart failure; ICD – implantable cardioverter-defibrilator; CRT – cardiac resynchronization therapy; SBP – systolic blood pressure; DBP – diastolic blood pressure; TIA – transient ischemic attack; CODP – chronic obstructive pulmonary disease; eGFR – estimated glomerular filtration rate; ACE-I – angiotensin-converting enzyme inhibitor; ARB – angiotensin receptor blocker.